|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
1
|
|
pubmed:dateCreated |
2003-2-10
|
|
pubmed:abstractText |
To analyze the evolution of clinical lipodystrophy (LD) and metabolic abnormalities in patients continuing to receive HAART versus patients switched to Trizivir (zidovudine, lamivudine, abacavir) after 48 weeks.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:issn |
1528-4336
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
4
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
37-43
|
|
pubmed:dateRevised |
2006-9-18
|
|
pubmed:meshHeading |
pubmed-meshheading:12577195-Adult,
pubmed-meshheading:12577195-Anti-HIV Agents,
pubmed-meshheading:12577195-Antiretroviral Therapy, Highly Active,
pubmed-meshheading:12577195-Blood Glucose,
pubmed-meshheading:12577195-Dideoxynucleosides,
pubmed-meshheading:12577195-Drug Combinations,
pubmed-meshheading:12577195-Female,
pubmed-meshheading:12577195-HIV Infections,
pubmed-meshheading:12577195-HIV-1,
pubmed-meshheading:12577195-HIV-Associated Lipodystrophy Syndrome,
pubmed-meshheading:12577195-Humans,
pubmed-meshheading:12577195-Lamivudine,
pubmed-meshheading:12577195-Lipids,
pubmed-meshheading:12577195-Male,
pubmed-meshheading:12577195-Metabolic Diseases,
pubmed-meshheading:12577195-Time Factors,
pubmed-meshheading:12577195-Zidovudine
|
|
pubmed:articleTitle |
Comparison of metabolic abnormalities and clinical lipodystrophy 48 weeks after switching from HAART to Trizivir versus continued HAART: the Trizal study.
|
|
pubmed:affiliation |
Department of Infectious Diseases, Chalucet Hospital, Toulon, France. avps@club-internet.fr
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Randomized Controlled Trial
|
